Gastroenterology 85 , 11201130 (1983)
3.5 cm (placebo) Cardiometabolic Benefits: Improvements in blood pressure, lipids, and glycemic parameters Safety: GI events dose-dependent
Interestingly, a smaller BMO diameter appears to correspond to fewer systemic risk factors
JAMA (2013) 310(9):948 959
The largest psychiatric safety meta-analysis to date found that GLP-1 medications were not associated with increased risk of serious psychiatric adverse events overall ( Pierret et al., JAMA Psychiatry, 2025 ), and a post-hoc analysis of the major semaglutide weight management trials found no differences in depression, suicidal ideation, or suicidal behavior compared to placebo ( Wadden et al., JAMA Internal Medicine, 2024 )
Where to buy 5-Amino-1MQ for weight loss When buying peptides, always research and exercise due diligence